Recent Updates
Recently added Catalysts
IMVT Positive Sentiment

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Wednesday, January 3, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immunovant, Inc. announced that its CEO, Pete Salzmann, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation aims to outline the company's initiatives and developments in targeting autoimmune diseases through anti-FcRn technology. Stakeholders can access the live webcast and an archived version on Immunovant's website post-presentation. This showcases the company's ongoing commitment to innovation in immunology.
Price reaction · baseline $41.39 (2024-01-02 close) · hit after-hours · clean, no other IMVT news in the window
day 0 close · peak
-6.3%
day 1
-6%
day 3
+4.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is actively engaging with stakeholders by presenting at a significant healthcare conference.
  • The company is focused on addressing the needs of people with autoimmune diseases through innovative therapies.
  • Immunovant has a strong leadership presence with CEO Pete Salzmann presenting at the conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
7.3%
average across 5 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
IMVT-1402
Phase 3 · Generalized Myasthenia Gravis

Full Press Release Details

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am ET.
The presentation will be webcast live and can be accessed at https://www.immunovant.com/investors/news-events. An archived webcast will be available for a limited time on Immunovant’s website.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.
Chau Cheng, PhD, MBA

Frequently Asked Questions

When will Immunovant present at the J.P. Morgan Conference?

Immunovant will present on January 9, 2024, at 10:30 am ET.

How can I access the Immunovant conference presentation?

The presentation will be webcast live on Immunovant's website.

What is the focus of Immunovant, Inc.?

Immunovant focuses on developing therapies for autoimmune diseases.

Who is presenting at the J.P. Morgan Healthcare Conference?

Pete Salzmann, M.D., the CEO, will provide the corporate overview.

What technology does Immunovant specialize in?

Immunovant specializes in anti-FcRn technology for autoimmune treatments.

ShareAdd on Google
Tags: IMVT Viatris Investor Conferences Healthcare Immunovant autoimmune diseases J.P. Morgan Healthcare Conference Pete Salzmann anti-FcRn technology
Last updated: Jan 3, 2024

Biotech snapshot

Cash runway
$798M liquidity · $41M/mo burn
~19 mo
Low dilution risk
Lead asset
IMVT-1402Phase 3
Generalized Myasthenia Gravis →

Catalyst track record

+85%
best trade around IMVT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for IMVT.

See every catalyst's timing & PoA →